Kairos Pharma Files 8-K
Ticker: KAPA · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1962011
Sentiment: neutral
Topics: 8-K, filing, exhibits
TL;DR
Kairos Pharma filed an 8-K, likely procedural or containing exhibit updates.
AI Summary
On September 11, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific material events, financial figures, or new developments were detailed in the provided excerpt.
Why It Matters
This filing indicates Kairos Pharma, Ltd. has submitted a current report to the SEC, which may contain material updates, though the specific details are not elaborated in this excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant risks or negative events.
Key Players & Entities
- Kairos Pharma, Ltd. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Kairos Pharma, Ltd.?
The filing is primarily for "Other Events" and "Financial Statements and Exhibits" as per the report.
When was the earliest event reported in this filing?
The earliest event reported is dated September 11, 2025.
What is the state of incorporation for Kairos Pharma, Ltd.?
Kairos Pharma, Ltd. is incorporated in Delaware.
What is the business address of Kairos Pharma, Ltd.?
The business address is 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
What is the SIC code for Kairos Pharma, Ltd.?
The Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 568 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-09-11 08:00:39
Key Financial Figures
- $0 — ch registered Common Stock, par value $0.001, per share KAPA NYSE American
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001493152-25-013040.txt ( ) — 228KB
- kapa-20250911.xsd (EX-101.SCH) — 3KB
- kapa-20250911_lab.xml (EX-101.LAB) — 33KB
- kapa-20250911_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2025 Kairos Pharma, Ltd. (Exact name of registrant as specified in its charter) Delaware 001-42275 46-2993314 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (Address of principal executive offices) (Zip Code) (310) 948-2356 Registrant's telephone number, including area code N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol (s) Name of each exchange on which registered Common Stock, par value $0.001, per share KAPA NYSE American Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. On September 11, 2025, Kairos Pharma, Ltd., a Delaware corporation (the "Company"), issued a press release announcing that it will host a premier KOL event on Thursday, September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company's interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Item 8.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01, including Exhibit 99.1. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 11, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 11, 2025 KAIROS PHARMA, LTD. By: /s/ John S. Yu John S. Yu Chief Executive Officer